Corindus Vascular Robotics Inc (A:CVRS)

Business Focus: Advanced Medical Equipment & Technology

Mar 12, 2019 16:05 ET
Corindus Reports Fourth Quarter and Full Year 2018 Results
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its fourth quarter and year ended December 31, 2018.
Mar 12, 2019 08:41 ET
Corindus Vascular Robotics Announces Additional Closing of Private Placement
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced the execution of an additional closing of the private placement previously announced on February 26, 2019. In the additional closing, existing investors with preemptive rights purchased an aggregate of 3,512,124 shares of the Company’s common stock on the same terms and at the same price of $1.3796 per share as the initial closing through the exercise of such preemptive rights and the purchase
Mar 05, 2019 06:50 ET
Corindus to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release fourth quarter and full year 2018 financial and business results on Tuesday, March 12, 2019 after the close of the U.S. financial markets.
Mar 05, 2019 06:45 ET
Corindus to Present at 39th Annual Cowen Health Care Conference on March 13, 2019
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, will present at the 39th Annual Cowen Health Care Conference as follows:
Feb 26, 2019 09:17 ET
Corindus Vascular Robotics Announces Closing of Private Placement for $15 Million
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American:CVRS), a leading developer of precision vascular robotics, today announced the execution of a private placement transaction with a large institutional investor pursuant to which it will sell and issue an aggregate of 10,872,716 shares of its common stock, at a purchase price of $1.3796 per share, resulting in aggregate gross proceeds to the Company of approximately $15 million, which the Company expects to receive during the day. The net proceeds are expected to be
Feb 14, 2019 06:45 ET
Corindus Announces FDA Submission for Neurovascular Intervention Indication for CorPath® GRX Vascular Robotic System
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it is seeking premarket clearance from the
Dec 06, 2018 06:45 ET
Corindus’ Technology Successfully Used in World’s First-in-Human Telerobotic Coronary Intervention
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announces that its CorPath technology was used to conduct the first-in-human (FIH) Telerobotic Intervention Study, December 4 and 5, 2018, in India. This study represents the world’s first percutaneous coronary i
Nov 28, 2018 08:10 ET
Consolidated Research: 2018 Summary Expectations for Kadmon, Overstock, AECOM, Steelcase, CorMedix, and Corindus Vascular Robotics — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kadmon Holdings, Inc. (NYSE:KDMN), Overstock.com, Inc. (NASDAQ:OSTK),...
Nov 07, 2018 16:30 ET
Corindus to Present at Upcoming 2018 Healthcare Conferences
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that management will present at two investor conferences in November as follows:
Nov 06, 2018 16:05 ET
Corindus Reports Third Quarter 2018 Results
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today reported financial results for its third quarter ended September 30, 2018.
Oct 30, 2018 16:30 ET
Corindus to Report Third Quarter Financial Results on November 6, 2018
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the third quarter of 2018 on Tuesday, November 6, 2018 after the close of the U.S. financial markets.
Oct 18, 2018 07:55 ET
Market Trends Toward New Normal in LSC Communications, Corindus Vascular Robotics, Sprouts Farmers Market, Luminex, ChromaDex, and CareDx — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LSC Communications (NYSE:LKSD), Corindus Vascular Robotics, Inc....
Oct 01, 2018 06:45 ET
Corindus Technology Successfully used in Multiple Live Complex Robotic-Assisted Coronary Interventions at Transcatheter Cardiovascular Therapeutics 2018
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that its CorPath GRX System was used for multiple complex robotic-assisted percutaneous coronary interventions (PCI) at the recent Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference. I
Sep 24, 2018 06:45 ET
Corindus Announces First Live Transmission of Remote Robotic Demonstration Performed at Transcatheter Cardiovascular Therapeutics 2018 Conference
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced the first live transmission of a remote interventional procedure using the company’s CorPath® platform was performed at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Diego
Sep 17, 2018 16:30 ET
Corindus to Present at Ladenburg Thalmann 2018 Healthcare Conference
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference as follows:
Sep 14, 2018 06:45 ET
Corindus to Feature the CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics 2018 Conference
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, will feature its CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference, September 21 – 25, in San Diego, CA. Corindus' CorPath GRX is the first FDA-cleared medical devi
Aug 23, 2018 06:45 ET
Corindus to Present at 13th Annual Wells Fargo Securities Healthcare Conference
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, will present at the 13th Annual Wells Fargo Securities Healthcare Conference. Details for the presentation include:
Aug 07, 2018 16:05 ET
Corindus Reports Second Quarter 2018 Results
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today reported financial results for its second quarter ended June 30, 2018.
Aug 06, 2018 06:45 ET
Corindus to Showcase CorPath GRX® System for Peripheral Vascular Interventions at the 2018 Amputation Prevention Symposium
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that the CorPath GRX System will be showcased for peripheral applications at the 2018 Amputation Prevention Symposium in Chicago, IL. Jihad Mustapha, M.D., Interventional Cardiologist and AMP course d
Aug 03, 2018 06:45 ET
Corindus to Present at Canaccord Genuity 38th Annual Growth Conference
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced the company plans to participate in the 38th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA.
Aug 03, 2018 06:45 ET
Corindus to Report Second Quarter Financial Results on August 7, 2018
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the second quarter of 2018 after the close of trading on Tuesday, August 7, 2018.
Jul 19, 2018 08:49 ET
Corindus Announces Significant Progress in the Development of Remote Vascular Robotic Technology with the CorPath GRX® System
Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that Ryan Madder, M.D., an interventional cardiologist at Spectrum Health, has successfully completed a remote percutaneous coronary intervention (PCI) in a porcine model using the CorPath GRX System f
Jul 11, 2018 06:45 ET
Corindus Names Aquilla S. Turk, D.O. as Chief Medical Officer, Neuroendovascular
Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that Aquilla "Quill" Turk, D.O. has joined the company as Chief Medical Officer, Neuroendovascular. Dr. Turk is a practicing physician at the Medical University of South Carolina where he serves as Dir
Jun 20, 2018 08:30 ET
Investor Expectations to Drive Momentum within John Bean Technologies, Arlington Asset Investment, Vuzix, HFF, Blackbaud, and Corindus Vascular Robotics — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of John Bean Technologies Corporation (NYSE:JBT), Arlington Asset Investment...
Jun 19, 2018 06:45 ET
Corindus Promotes Doug Teany to Chief Operating Officer
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has appointed Douglas Teany, currently the company’s Senior Vice President of R&D and Operations, to Chief Operating Officer, effective immediately.
Jun 08, 2018 09:00 ET
Corindus Announces Pharmaceutical and Medical Device Agency (PMDA) Approval of CorPath GRX System in Japan
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it received Pharmaceutical and Medical Device Agency (PMDA) Approval for commercialization of its CorPath® GRX System in Japan. Japan is one of the largest markets in the world for per
May 08, 2018 16:05 ET
Corindus Reports First Quarter 2018 Results
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its first quarter ended March 31, 2018.
Apr 27, 2018 16:05 ET
Corindus to Report First Quarter Financial Results on May 8, 2018
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the first quarter of 2018 after the close of trading on Tuesday, May 8, 2018. The Company’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Apr 26, 2018 08:10 ET
Market Trends Toward New Normal in FormFactor, Corindus Vascular Robotics, Syntel, IQVIA Holdings, Hannon Armstrong Sustainable Infrastructure Capital, and Ennis — Emerging Consolidated Expectations,
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FormFactor, Inc. (NASDAQ:FORM), Corindus Vascular Robotics,...
Apr 23, 2018 06:45 ET
Corindus Presents "Optimizing Care with CorPath GRX: Hot Topics in Robotic Interventions" at SCAI 2018 Dinner Symposium on April 26
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will sponsor a dinner event during the Society for Cardiovascular Angiography and Interventions (
Mar 16, 2018 09:15 ET
Corindus Announces $25 Million Private Placement of Series A Convertible Preferred Shares and Warrants
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has entered into definitive agreements to issue newly-designated Series A Convertible Preferred Stock to a select group of existing investors including Hudson Executive Capital and BioStar Ven
Mar 14, 2018 16:05 ET
Corindus Reports Fourth Quarter and Full Year 2017 Results
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its fourth quarter and year ended December 31, 2017.
Mar 13, 2018 16:02 ET
Corindus to Report Fourth Quarter and Full Year 2017 Financial Results on March 14, 2018
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the fourth quarter of 2017 after the close of trading on Wednesday, March 14, 2018. The Company’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Mar 13, 2018 07:00 ET
James R. Tobin Joins Corindus Board of Directors
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that James (Jim) Tobin has been appointed to its Board of Directors, effective immediately.
Mar 12, 2018 16:30 ET
Corindus to Present at Cowen Health Care Conference
Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced the company plans to participate in the 38th Annual Health Care Conference hosted by Cowen in Boston, MA.
Mar 05, 2018 06:45 ET
Corindus Receives FDA Clearance for First Automated Robotic Movement in technIQ™ Series for CorPath GRX Platform
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for the CorPath GRX platform.
Mar 01, 2018 08:10 ET
Recent Analysis Shows Mobile Mini, Corindus Vascular Robotics, Payment Data, STAAR Surgical, Voyager Therapeutics, and Sunshine Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mobile Mini, Inc. (NASDAQ:MINI), Corindus Vascular...
Feb 22, 2018 06:45 ET
Delray Beach Medical Center Performs First Robotic-Assisted Peripheral Vascular Intervention Using Corindus CorPath® GRX System Following FDA Clearance
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today the successful completion of the first robotic-assisted peripheral vascular intervention procedure using the recently FDA-cleared CorPath GRX System. The procedure was performed by Joseph Ricotta, M.D., Medical Director of Vascular Surgery and Endovascular Therapy, Tenet Healthcare, Professor of Surgery, Charles E Schmidt College of Medicine, FAU. CorPath GRX is the first and only FDA-cleared medical device to bring
Feb 20, 2018 06:45 ET
Corindus Receives FDA Clearance for CorPath® GRX System in Peripheral Vascular Interventions
Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use of its CorPath GRX System in peripheral vascular interventions. The CorPath System is the first and only FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) procedures.
Jan 23, 2018 17:15 ET
Corindus to Co-Sponsor Courses at Multiple Leading Healthcare Institutions on Value-based Interventional Procedural Training
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced it will co-sponsor courses at multiple leading hospitals to educate interventional cardiologists on transradial access techniques and robotic-assisted vascular interventions. The course series entitled "Complex Radial Interventions on Robotic and Manual Platforms" is designed to familiarize participants with the operations and capabilities of robotic-assisted percutaneous coronary interventions (PCI) using the CorPath GRX
Jan 23, 2018 17:00 ET
Corindus Announces Preliminary Fourth Quarter and Full Year 2017 Revenue
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported preliminary revenue results for the fourth quarter and year ended December 31, 2017.
Jan 04, 2018 08:15 ET
Detailed Research: Economic Perspectives on Athersys, Repros Therapeutics, GCP Applied Technologies, IDACORP, Mobile Mini, and Corindus Vascular Robotics — What Drives Growth in Today's Competitive La
NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Athersys, Inc. (NASDAQ:ATHX), Repros Therapeutics Inc....
Jan 02, 2018 16:30 ET
Corindus to Participate with Mayo Clinic in Preclinical Study of Remote Control Robotics for Percutaneous Coronary Interventions Remote Treatment Capabilities
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it is working with Mayo Clinic in a preclinical study about use of telestenting. Telestenting, or the remote robotic treatment for percutaneous coronary intervention (PCI), may enable physicians to conduct procedures from virtually any location, opening opportunities for more patients globally to receive the benefits of this lifesaving procedure. The global shortage of PCI-capable operators is significant and co
Dec 14, 2017 06:45 ET
Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
Corindus Vascular Robotics, Inc.(NYSE American: CVRS), a leading developer of precision vascular robotics, announced today the first commercial installation of a CorPath GRX System outside of the United States. The system was purchased by the Apex Heart Institute in Ahmedabad, India, a state of the art cardiology center. Corindus will partner with Apex Heart Institute to develop a Global Center of Excellence to train interventional cardiologists on robotic-assisted percutaneous coronary interventions (PCI).
Dec 01, 2017 06:45 ET
Corindus Partners with Houston Methodist DeBakey Heart & Vascular Center to Launch Premier Robotic Training Site for Physicians
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Houston Methodist DeBakey Heart & Vascular Center, a leading cardiovascular center located in the Texas Medical Center, has launched the first vascular robotic program in the Houston area with the installation of two CorPath® GRX Systems. In addition and as part of the program launch, Corindus will partner with Houston Methodist to develop a Global Center of Excellence that will seek to advance clinical
Nov 07, 2017 16:05 ET
Corindus Vascular Robotics Reports Third Quarter 2017 Results
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for the quarter ended September 30, 2017.
Nov 02, 2017 16:15 ET
Corindus to Present at Upcoming Investor Conferences
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced the Company will be participating in two upcoming investor conferences.
Oct 27, 2017 16:37 ET
Corindus to Feature CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics 2017 Conference
Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that it will be participating in the Transcatheter Cardiovascular Therapeutics (TCT) 2017 Conference to be held October 29 – November 2 in Denver, CO. Robotic-assisted percutaneous coronary intervention (PCI) will be featured throughout the conference, including in the exhibit hall, presentations, and during a breakfast symposium.
Oct 24, 2017 16:15 ET
Corindus Vascular Robotics to Report Third Quarter 2017 Financial Results on November 7, 2017
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it will release financial and business results for the second quarter of 2017 after the close of trading on Tuesday, November 7, 2017. The Company’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Oct 23, 2017 06:45 ET
Corindus Evaluates Incorporating HeartFlow Technology with CorPath GRX System
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will incorporate the HeartFlow® FFRct Analysis in a case series of robotic-assisted percutaneous coronary intervention (PCI) procedures with the CorPath® GRX System to evaluate the feasibility and utility of clinical decision support.